Destaques

Opinião | Por que demorou 2 anos para a OMS dizer que a COVID é transmitida pelo ar.

11 Abr, 2022 | 12:55h

Why the WHO took two years to say COVID is airborne – Nature

---

Experiências positivas no centro da atenção pós-natal.

11 Abr, 2022 | 12:54h

Putting positive experiences at the centre of postnatal care – Evidently Cochrane Blog

Diretriz original: WHO recommendations on maternal and newborn care for a positive postnatal experience.

---

M-A | Desempenho diagnóstico do CO-RADS para Covid-19.

11 Abr, 2022 | 12:53h

Diagnostic performance of CO-RADS for COVID-19: a systematic review and meta-analysis – European Radiology

Conteúdos relacionados: CO-RADS – A categorical CT assessment scheme for patients with suspected COVID-19: definition and evaluation – Radiology

---

Estudo mostra risco aumentado de embolia pulmonar em até 110 dias após a COVID-19.

8 Abr, 2022 | 21:58h

Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study – The BMJ

Comunicado de imprensa: Study finds increased risk of serious blood clots up to six months after COVID-19 – BMJ

Editorial: Thromboembolism and bleeding after covid-19

Comentário: Covid: Blood clot risk higher for six months after having virus – BBC

---

COVID-19: diretriz conjunta do ECDC e EMA sobre a 4ª dose de vacinas de mRNA.

8 Abr, 2022 | 21:56h

COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines –
European Centre for Disease Prevention and Control

Conteúdos relacionados:

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter (fio – clique para saber mais)

#JustPublished!#ECDC and @EMA_News issue advice on fourth doses of mRNA #COVID19 vaccines.

Read the full joint statement: https://t.co/hBuOlrfKOD pic.twitter.com/aO5vSyYvTk

— ECDC (@ECDC_EU) April 6, 2022

 

---

Estudo randomizado pragmático | Em pacientes ambulatoriais com COVID-19, a adição da oximetria de pulso para monitoramento não melhorou os desfechos em comparação a avaliações subjetivas isoladas da dispneia.

8 Abr, 2022 | 21:54h

Pulse Oximetry for Monitoring Patients with Covid-19 at Home — A Pragmatic, Randomized Trial – New England Journal of Medicine

 

Comentário no Twitter

A potential practice changer by @kit_delgadoMD et al in NEJM today.

At-home pulse oximeters did NOT improve outcomes.

Important to focus on things that help.

If these devices don't help, then we shouldn't routinely advise them.

Super interesting work.https://t.co/VDDyRLw7ba

— Jeremy Faust MD MS (ER physician) (@jeremyfaust) April 6, 2022

 

---

M-A | Fluvoxamina no tratamento ambulatorial da COVID-19 para evitar internação.

8 Abr, 2022 | 21:52h

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis – JAMA Network Open

Comentário: Common Antidepressant Likely Cuts Risk Of Covid Hospitalization, Study Finds – Forbes

Conteúdos relacionados:

Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Comentário no Twitter

Bayesian SRMA of 3 RCTs showed a high prob (94-98.6%) that fluvoxamine is associated with reduced risk of hospitalization for outpatients with #COVID19, (RR 0.75). @DrEmilyMcD @DrToddLee @simonevigod @AngelaReiersen @boulware_dr https://t.co/ctMKzBDbzP

— JAMA Network Open (@JAMANetworkOpen) April 6, 2022

 

---

Estudo randomizado | Entre pacientes com infecção complicada de trato urinário, o uso oral de tebipenem pivoxil hidrobromida foi não inferior ao ertapenem intravenoso e mostrou perfil de segurança similar.

8 Abr, 2022 | 21:50h

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection – New England Journal of Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

For complicated UTI or acute pyelonephritis, oral tebipenem pivoxil hydrobromide noninferior to IV ertapenem and has a similar safety profile. https://t.co/FRDMQOD0Pn pic.twitter.com/GFQz7SlciX

— NEJM (@NEJM) April 6, 2022

 

---

Opinião | Auditoria dos algoritmos médicos.

8 Abr, 2022 | 21:49h

The medical algorithmic audit – The Lancet Digital Health

Artigo relacionado: Validation and algorithmic audit of a deep learning system for the detection of proximal femoral fractures in patients in the emergency department: a diagnostic accuracy study – The Lancet Digital Health

Conteúdo relacionado: Health-related artificial intelligence needs rigorous evaluation and guardrails – STAT

 

Comentário no Twitter

“without the ability to observe and learn from algorithmic errors, the risk is that it will continue to happen and there's no accountability for any harm that results"
NEW Editorial: 'Holding #ArtificialIntelligence to account'.https://t.co/Dg3OtJZZT9 pic.twitter.com/JQbrXbbNqy

— The Lancet Digital Health (@LancetDigitalH) April 6, 2022

 

---

Estudo randomizado | Eficácia de longo prazo e segurança da denervação renal na presença de medicamentos anti-hipertensivos.

8 Abr, 2022 | 21:47h

Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial – The Lancet (link para o resumo – $ para o texto completo)

Comentário: Three-year trial of SPYRAL HTN-ON MED shows blood pressure reductions – MedicalXpress

Conteúdos relacionados:

Systematic Review: Renal denervation may have a modest effect in improving 24h ambulatory blood pressure monitoring (reduction in SBP by 5.29 mmHg and DBP by 3.75 mmHg) but does not improve major cardiovascular outcomes and renal function.

M-A: Renal denervation for hypertension is associated with a modest reduction in ambulatory blood pressure control (3.61 mm Hg reduction in ambulatory systolic BP and 1.85 mm Hg reduction in ambulatory diastolic BP).

#ACC21 – RCT: Among patients with resistant hypertension, ultrasound renal denervation resulted in a modest improvement in systolic BP (–4.5 mm Hg) vs. sham procedure.

Meta-Analysis: Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients with Hypertension

 

Comentário no Twitter

Renal denervation could provide an adjunctive treatment modality in the management of patients with #hypertension, suggests trial assessing long-term efficacy & safety in the presence of antihypertensive drugs: https://t.co/45ojbyhQp3 pic.twitter.com/eg6CXGDGCE

— The Lancet (@TheLancet) April 6, 2022

 

---